A drug best known for its role in controlling water balance may offer a crucial rescue option for newborns whose blood pressure remains dangerously low despite conventional treatment, according to a new review in the Journal of Perinatology. The article examines how vasopressin is being used to support circulation in neonates, particularly extremely premature infants and critically ill newborns with shock that does not respond adequately to standard therapies.
Vasopressin is a naturally occurring hormone produced in the hypothalamus and released by the posterior pituitary gland. In the bloodstream, it helps maintain vascular tone and regulate fluid balance. Its most important cardiovascular action in emergency care is mediated through V1a receptors located on vascular smooth-muscle cells. When these receptors are activated, the blood vessels constrict, increasing systemic vascular resistance and helping restore arterial pressure. This mechanism differs from that of catecholamines such as dopamine, dobutamine, and epinephrine, which primarily act through adrenergic receptors.
That difference has made vasopressin attractive in neonatal intensive care, where low blood pressure can arise from several overlapping problems. Immature blood vessels, weak myocardial function, infection, inflammation, respiratory failure, and the effects of mechanical ventilation can all reduce effective circulation in a newborn. In extremely preterm infants, the cardiovascular system may be unable to maintain sufficient pressure even when the heart rate appears adequate. The result can be impaired blood flow to the brain, kidneys, intestines, and other vital organs.
The review by Arjun Surak, Marwa Sewidan, Megan T. Y. Kuan, and colleagues describes vasopressin as a potential adjunct rather than a universal replacement for established treatments. Clinicians generally consider it when hypotension persists despite fluid assessment and the use of conventional vasoactive medicines. This situation is often described as catecholamine-refractory shock. In such cases, vasopressin may increase blood pressure without producing the same degree of tachycardia or myocardial oxygen demand associated with escalating doses of adrenergic drugs.
The hormone’s effects, however, are not limited to raising blood pressure. By constricting blood vessels, vasopressin can alter blood flow distribution throughout the body. Some clinical reports have suggested improved urine output and more stable systemic circulation in selected neonates, while other observations have raised concerns about reduced perfusion in the skin, gastrointestinal tract, or extremities. The balance between restoring an adequate arterial pressure and avoiding excessive vasoconstriction is therefore central to safe treatment.
Neonatal use is especially complicated because a newborn’s physiology changes rapidly after birth. Gestational age, birth weight, patent ductus arteriosus, lung disease, sepsis, renal function, and the state of the pulmonary circulation can all affect how vasopressin behaves. The drug may be considered in systemic vasodilatory shock, including some cases associated with severe infection, but its use requires careful differentiation between low vascular tone and other causes of hypotension, such as poor cardiac contractility or inadequate circulating volume.
Another area of interest is the relationship between vasopressin and pulmonary vascular resistance. In some circumstances, vasopressin may support systemic pressure while having a comparatively limited effect on the pulmonary circulation, a feature that could be useful when a newborn has pulmonary hypertension or right-ventricular strain. Yet this potential advantage cannot be assumed for every patient. The response depends on the underlying disease, the condition of the lungs, the degree of hypoxia, and the combination of other cardiovascular drugs being administered.
The evidence base remains considerably smaller than that available for many drugs used in neonatal intensive care. Much of the published experience comes from retrospective studies, small observational cohorts, case series, and single-center reports rather than large randomized clinical trials. These studies can identify patterns of response, but they cannot reliably establish whether vasopressin improves survival or long-term neurological development. They may also be affected by differences in patient selection, dosing strategies, timing of treatment, and the severity of illness at the moment the drug was started.
For that reason, the review emphasizes the need for individualized dosing and continuous monitoring. Neonatal teams must follow blood pressure trends alongside markers of organ perfusion, including urine output, capillary refill, lactate levels, peripheral temperature, and, when available, echocardiographic measurements of cardiac function and blood flow. Because excessive vasoconstriction can be harmful, clinicians must also watch for signs of reduced peripheral or intestinal circulation. Vasopressin is typically delivered as a carefully controlled intravenous infusion, and abrupt changes in therapy can produce rapid hemodynamic effects.
The authors present vasopressin as a promising but still incompletely defined tool in the neonatal pharmacological arsenal. Its distinct receptor activity may provide an important alternative when conventional catecholamines fail, especially in forms of vasodilatory shock. At the same time, the lack of standardized neonatal protocols and high-quality comparative trials means that practice varies between institutions. Future research will need to determine which newborns benefit most, when treatment should begin, how vasopressin should be combined with other vasoactive agents, and whether short-term improvements in blood pressure translate into better survival and development. Until those answers emerge, the drug’s role is likely to remain one of carefully monitored rescue support rather than routine first-line therapy.
Subject of Research: Vasopressin for hemodynamic support in critically ill neonates, including its mechanisms, clinical applications, benefits, risks, and evidence limitations.
Article Title: Vasopressin for hemodynamic support in neonates: current evidence and clinical applications
Article References: Surak, A., Sewidan, M., Kuan, M.T.Y. et al. “Vasopressin for hemodynamic support in neonates: current evidence and clinical applications.” Journal of Perinatology (2026). https://doi.org/10.1038/s41372-026-02837-0
Image Credits: AI Generated
DOI: 10.1038/s41372-026-02837-0
Keywords: vasopressin, neonates, neonatal intensive care, hemodynamic support, hypotension, shock, catecholamine-refractory shock, premature infants, pulmonary hypertension, vasopressors, neonatal pharmacology
Tags: circulatory support in critically ill newbornsemergency pharmacology for neonatal circulationhormone therapy for newborn blood pressurelow blood pressure treatment in preterm infantsmanagement of hypotension in newbornsneonatal shock managementneonatal shock treatment optionsneonatal vasopressin therapyV1a receptor mechanisms in neonatesvasopressin in neonatal intensive carevasopressin role in maintaining vascular tonevasopressin versus catecholamines
